BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15571987)

  • 1. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice.
    Liu L; Herukka SK; Minkeviciene R; van Groen T; Tanila H
    Neurobiol Dis; 2004 Dec; 17(3):516-23. PubMed ID: 15571987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
    Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR
    Neurobiol Dis; 2005 Apr; 18(3):602-17. PubMed ID: 15755686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease.
    Wirths O; Thelen K; Breyhan H; Luzón-Toro B; Hoffmann KH; Falkai P; Lütjohann D; Bayer TA
    Exp Gerontol; 2006 Feb; 41(2):220-4. PubMed ID: 16307858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1.
    Jankowsky JL; Slunt HH; Gonzales V; Jenkins NA; Copeland NG; Borchelt DR
    Neurobiol Aging; 2004 Aug; 25(7):885-92. PubMed ID: 15212842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
    Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
    J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
    Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
    J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate.
    Cohen MP; Shearman CW
    Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1099-103. PubMed ID: 19413589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
    Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
    Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43).
    Mann DM; Iwatsubo T; Cairns NJ; Lantos PL; Nochlin D; Sumi SM; Bird TD; Poorkaj P; Hardy J; Hutton M; Prihar G; Crook R; Rossor MN; Haltia M
    Ann Neurol; 1996 Aug; 40(2):149-56. PubMed ID: 8773595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.
    De Jonghe C; Cras P; Vanderstichele H; Cruts M; Vanderhoeven I; Smouts I; Vanmechelen E; Martin JJ; Hendriks L; Van Broeckhoven C
    Neurobiol Dis; 1999 Aug; 6(4):280-7. PubMed ID: 10448055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1.
    Shimojo M; Sahara N; Murayama M; Ichinose H; Takashima A
    Neurosci Res; 2007 Mar; 57(3):446-53. PubMed ID: 17210196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
    Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
    Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice.
    Oksman M; Iivonen H; Hogyes E; Amtul Z; Penke B; Leenders I; Broersen L; Lütjohann D; Hartmann T; Tanila H
    Neurobiol Dis; 2006 Sep; 23(3):563-72. PubMed ID: 16765602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1.
    Szapacs ME; Numis AL; Andrews AM
    Neurobiol Dis; 2004 Aug; 16(3):572-80. PubMed ID: 15262269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice.
    Herzig MC; Paganetti P; Staufenbiel M; Jucker M
    Neurodegener Dis; 2007; 4(2-3):127-35. PubMed ID: 17596707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.
    Bentahir M; Nyabi O; Verhamme J; Tolia A; Horré K; Wiltfang J; Esselmann H; De Strooper B
    J Neurochem; 2006 Feb; 96(3):732-42. PubMed ID: 16405513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.